Also known as: FTS · Facteur Thymique Serique · Serum Thymic Factor
Thymulin is a zinc-dependent nonapeptide hormone produced exclusively by thymic epithelial cells (TECs). Its biological activity is entirely dependent on zinc chelation — apo-thymulin (zinc-free) is inactive. It is the most specific marker of thymic function and declines sharply with age, thymic involution, and zinc deficiency.
Thymulin was isolated in 1977 by Mireille Dardenne and Jean-François Bach at INSERM Paris. It is unique among thymic hormones in being the only one produced exclusively by thymic epithelial cells (not lymphocytes), making it a highly specific biomarker of thymic endocrine function. Plasma levels decline dramatically after puberty in parallel with thymic involution.
Beyond immune function, thymulin has demonstrated significant analgesic properties in rodent models of inflammatory and neuropathic pain — a finding that has driven investigation of gene therapy approaches (intranasal AAV delivery of thymulin-expressing constructs) as a novel pain treatment strategy.
Thymulin-Zn²⁺ complex binds to specific receptors on early T-cell precursors, promoting expression of T-cell surface markers (CD2, CD3, CD4, CD8) and MHC-restricted antigen recognition. It facilitates the final steps of intrathymic T-cell education, including positive and negative selection — processes that ensure functional but self-tolerant T-cells enter circulation.
Thymulin inhibits pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) in spinal cord microglia and dorsal root ganglia, reducing central sensitization in neuropathic pain states. It also increases β-endorphin production in the CNS — providing an opioid-independent analgesic component.
Ask anything about Thymulin — mechanisms, dosing protocols, interactions, or research comparisons.